#Tybost

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.

Non-alcoholic fatty liver disease can lead to more severe, potentially fatal liver diseases, including cirrhosis.

Protease inhibitors, including those used for hep C, and various other drugs may cause drug-drug interactions with statins.

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

Janssen’s single-tablet antiretroviral regimen was approved on July 17.

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.

Those on Tybost-boosted Vitekta are more than twice as likely as those taking Tivicay to switch meds because of adverse health events.

A new large study compared the single-tablet regimen with an equivalent containing a different version of tenofovir.

A small study of Spanish people with HIV taking Prezista (darunavir) found that cholesterol and triglycerides dropped after the switch.

Results from a Phase III trial showed Symtuza worked as well as a boosted protease inhibitor–based antiretroviral regimen.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

Gilead Sciences’ HCV combo tablet regimen of Sovaldi and velpatasvir can be combined safely with most “boosted” antiretroviral treatment...